SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His Recombinant Protein

COVID-19 Spike Research.
1/2
Price:
Size:
Number:

SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His Recombinant Protein: 产品信息

纯度
> 90 % as determined by SDS-PAGE.
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
生物活性
The 2019-nCoV Spike Protein (S1+S2 ECD, His tag) can bind with Human ACE2 in functional ELISA assay.
蛋白构建
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike Protein (S1+S2 ECD) (YP_009724390.1) (Val 16-Pro1213) was expressed with a polyhistidine tag at the C-terminus.
表达宿主
Baculovirus-Insect Cells
种属
2019-nCoV
预测 N 端
Val 16
分子量
The recombinant SARS-CoV-2 (2019-nCoV) Spike Protein (S1+S2 ECD, His tag) consists of 1209 amino acids and predicts a molecular mass of 134.36 kDa.
缓冲液
Lyophilized from sterile 20 mM Tris, 300 mM NaCl, 10 % glycerol, pH 8.0.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
运输方式
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
稳定性 & 储存条件
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
复溶
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His Recombinant Protein: 图片

Measured by its binding ability in a functional ELISA. Immobilized human ACE2 protein (Fc tag) (10108-H05H) at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His (40589-V08B1), the EC50 of SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His (40589-V08B1) is 400-1200 ng/mL.

SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His Recombinant Protein: 别称

coronavirus spike Protein, 2019-nCoV; cov spike Protein, 2019-nCoV; ncov RBD Protein, 2019-nCoV; ncov s1 Protein, 2019-nCoV; ncov s2 Protein, 2019-nCoV; ncov spike Protein, 2019-nCoV; NCP-CoV RBD Protein, 2019-nCoV; NCP-CoV s1 Protein, 2019-nCoV; NCP-CoV s2 Protein, 2019-nCoV; NCP-CoV Spike Protein, 2019-nCoV; novel coronavirus RBD Protein, 2019-nCoV; novel coronavirus s1 Protein, 2019-nCoV; novel coronavirus s2 Protein, 2019-nCoV; novel coronavirus spike Protein, 2019-nCoV; RBD Protein, 2019-nCoV; S1 Protein, 2019-nCoV; S2 Protein, 2019-nCoV; Spike RBD Protein, 2019-nCoV

Coronavirus spike 背景信息

The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, O-acetylated sialic acid. The spike is essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It's been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.
参考文献
  • Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35.
  • Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36.
  • Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.

2019-nCoV Coronavirus spike 蛋白

  • Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray
    Author
    De Assis, RR;Jain, A;Nakajima, R;Jasinskas, A;
    Year
    2020
    Journal
    BioRxiv
  • Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray
    Author
    Khan, S;Nakajima, R;Jain, A;De Assis, RR;Jasinskas, A;
    Year
    2020
    Journal
    BioRxiv
  • Cholesterol Metabolism--Impact for SARS-CoV-2 Infection Prognosis, Entry, and Antiviral Therapies
    Author
    Wei, C;Wan, L;Zhang, Y;Fan, C;Yan, Q;Yang, X;Gong, J;
    Year
    2020
    Journal
    medRxiv
  • COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva
    Author
    Randad, PR;Pisanic, N;Kruczynski, K;Manabe, YC;
    Year
    2020
    Journal
    medRxiv
  • Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein
    Author
    Song, Y;Song, J;Wei, X;Huang, M;Sun, M;Zhu, L;Lin, B;Shen, H;Zhu, Z;Yang, C;
    Year
    2020
    Journal
    ChemRxiv
  • Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein
    Author
    Feng, S;Luan, X;Wang, Y;Wang, H;Zhang, Z;Wang, Y;Tian, Z;Liu, M;Xiao, Y;Zhao, Y;Zhou, R;Zhang, S;
    Year
    2020
    Journal
    Infect. Genet. Evol.
  • Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain
    Author
    Chi, X;Liu, X;Wang, C;Zhang, X;Ren, L;Jin, Q;Wang, J;
    Year
    2020
    Journal
    bioRxiv
  • Immunogenicity of a DNA vaccine candidate for COVID-19
    Author
    Smith, TRF;Patel, A;Ramos, S;Elwood, D;Zhu, X;Yan, J;Gary, EN;Walker, SN;Schultheis, K;Purwar, M;Xu, Z;Walters, J;Bhojnagarwala, P;Yang, M;Chokkalingam, N;Pezzoli, P;Parzych, E;Reuschel, EL;Doan, A;Tursi, N;Vasquez, M;Choi, J;Tello-Ruiz, E;Maricic, I;Bah, MA;Wu, Y;Amante, D;Park, DH;Dia, Y;Ali, AR;Zaidi, FI;Generotti, A;Kim, KY;Herring, TA;Reeder, S;Andrade, VM;Buttigieg, K;Zhao, G;Wu, JM;Li, D;Bao, L;Liu, J;Deng, W;Qin, C;Brown, AS;Khoshnejad, M;Wang, N;Chu, J;Wrapp, D;McLellan, JS;Muthumani, K;Wang, B;Carroll, MW;Kim, JJ;Boyer, J;Kulp, DW;Humeau, LMPF;Weiner, DB;Broderick, KE;
    Year
    2020
    Journal
    Nat Commun
  • Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells
    Author
    Cao, Y;Su, B;Guo, X;Sun, W;Deng, Y;Bao, L;Zhu, Q;Zhang, X;Zheng, Y;Geng, C;Chai, X;He, R;Li, X;Lv, Q;Zhu, H;Deng, W;Xu, Y;Wang, Y;Qiao, L;Tan, Y;Song, L;Wang, G;Du, X;Gao, N;Liu, J;Xiao, J;Su, XD;Du, Z;Feng, Y;Qin, C;Qin, C;Jin, R;Xie, XS;
    Year
    2020
    Journal
    Cell
  • SARS-CoV-2 spike protein binds heparan sulfate in a length-and sequence-dependent manner
    Author
    Liu, L;Chopra, P;Li, X;Wolfert, MA;Tompkins, SM;
    Year
    2020
    Journal
    bioRxiv
    Application
    SPR
  • Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry
    Author
    Zhang, Y;Zhao, W;Mao, Y;Wang, S;Zhong, Y;Su, T;
    Year
    2020
    Journal
    bioRxiv
  • Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain
    Author
    Walter, JD;Hutter, CAJ;Zimmermann, I;Earp, J;Egloff, P;
    Year
    2020
    Journal
    BioRxiv
  • Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development
    Author
    Huang, S;Tai, C;Hsu, Y;Cheng, D;Hung, S;Chai, K;Wang, Y;Wang, J;
    Year
    2020
    Journal
    Biomedical Journal
  • SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
    Author
    Corbett, K;Edwards, D;Leist, S;Abiona, O;Boyoglu-Barnum, S;Gillespie, R;Himansu, S;Schäfer, A;Ziwawo, C;DiPiazza, A;Dinnon, K;Elbashir, S;Shaw, C;Woods, A;Fritch, E;Martinez, D;Bock, K;Minai, M;Nagata, B;Hutchinson, G;Bahl, K;Garcia-Dominguez, D;Ma, L;Renzi, I;Kong, W;Schmidt, S;Wang, L;Zhang, Y;Stevens, L;Phung, E;Chang, L;Loomis, R;Altaras, N;Narayanan, E;Metkar, M;Presnyak, V;Liu, C;Louder, M;Shi, W;Leung, K;Yang, E;West, A;Gully, K;Wang, N;Wrapp, D;Doria-Rose, N;Stewart-Jones, G;Bennett, H;Nason, M;Ruckwardt, T;McLellan, J;Denison, M;Chappell, J;Moore, I;Morabito, K;Mascola, J;Baric, R;Carfi, A;Graham, B;
    Year
    2020
    Journal
    bioRxiv
    Application
    immunization
  • SARS-CoV-2 environmental contamination associated with persistently infected COVID-19 patients
    Author
    Lei, H;Ye, F;Liu, X;Huang, Z;Ling, S;Jiang, Z;Cheng, J;Huang, X;Wu, Q;Wu, S;Xie, Y;Xiao, C;Ye, D;Yang, Z;Li, Y;Leung, NHL;Cowling, BJ;He, J;Wong, SS;Zanin, M;
    Year
    2020
    Journal
    Influenza Other Respir Viruses
    Application
    Elisa
  • SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients
    Author
    Walker, S;Chokkalingam, N;Reuschel, E;Purwar, M;Xu, Z;Gary, E;Kim, K;Schultheis, K;Walters, J;Ramos, S;Smith, T;Broderick, K;Tebas, P;Patel, A;Weiner, D;Kulp, D;
    Year
    2020
    Journal
    bioRxiv
    Application
    Elisa
  • Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patients
    Author
    Steiner, D;Cognetti, J;Luta, E;Klose, A;Bucukovski, J;Bryan, M;Schmuke, J;Nguyen-Contant, P;Sangster, M;Topham, D;Miller, B;
    Year
    2020
    Journal
    bioRxiv
  • Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
    Author
    Zhou, D;Duyvesteyn, H;Chen, C;Huang, C;Chen, T;Shih, S;Lin, Y;Cheng, C;Cheng, S;Huang, Y;Lin, T;Ma, C;Huo, J;Carrique, L;Malinauskas, T;Ruza, R;Shah, P;Tan, T;Rijal, P;Donat, R;Godwin, K;Buttigieg, K;Tree, J;Radecke, J;Paterson, N;Supasa, P;Mongkolsapaya, J;Screaton, G;Carroll, M;Jaramillo, J;Knight, M;James, W;Owens, R;Naismith, J;Townsend, A;Fry, E;Zhao, Y;Ren, J;Stuart, D;Huang, K;
    Year
    2020
    Journal
    bioRxiv
    Application
    Elisa
  • Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins
    Author
    Shi, Y;Shi, J;Sun, L;Tan, Y;Wang, G;Guo, F;Hu, G;Fu, Y;Fu, Z;Xiao, S;Peng, G;
    Year
    2020
    Journal
    bioRxiv
    Application
    Animal immunization; Elisa
  • A single dose of an adenovirus-vectored vaccine provides complete protection of the upper and lower respiratory tracts against SARS-CoV-2 challenge
    Author
    Wu, S;Zhong, G;Zhang, J;Shuai, L;Zhang, Z;Wen, Z;Wang, B;Zhao, Z;Song, X;Chen, Y;Liu, R;Fu, L;Zhang, J;Guo, Q;Wang, C;Yang, Y;Fang, T;Lv, P;Wang, J;Xu, J;Li, J;Yu, C;Hou, L;Bu, Z;Chen, W;
    Year
    2020
    Journal
    Research Square
  • Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions
    Author
    Kim, SY;Jin, W;Sood, A;Montgomery, DW;Grant, OC;Fuster, MM;Fu, L;Dordick, JS;Woods, RJ;Zhang, F;Linhardt, RJ;
    Year
    2020
    Journal
    Antiviral Res.
    Application
    SPR
  • SARS-CoV-2 surveillance for a non-human primate breeding research facility
    Author
    Yee, JL;Van Rompay, KKA;Carpenter, AB;Nham, PB;Halley, BM;Iyer, SS;Hartigan-O'Connor, DJ;Miller, CJ;Roberts, JA;
    Year
    2020
    Journal
    J. Med. Primatol.
    Application
    Elisa
  • A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies
    Author
    Acharya, P;Williams, W;Henderson, R;Janowska, K;Manne, K;Parks, R;Deyton, M;Sprenz, J;Stalls, V;Kopp, M;Mansouri, K;Edwards, RJ;Meyerhoff, RR;Oguin, T;Sempowski, G;Saunders, K;Haynes, BF;
    Year
    2020
    Journal
    bioRxiv
    Application
    Elisa
  • A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies
    Author
    Acharya, P;Williams, W;Henderson, R;Janowska, K;Manne, K;Parks, R;Deyton, M;Sprenz, J;Stalls, V;Kopp, M;Mansouri, K;Edwards, RJ;Meyerhoff, RR;Oguin, T;Sempowski, G;Saunders, K;Haynes, BF;
    Year
    2020
    Journal
    bioRxiv
  • Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency
    Author
    Du, S;Cao, Y;Zhu, Q;Wang, G;Du, X;He, R;Xu, H;Zheng, Y;Wang, B;Bai, Y;Ji, C;Yisimayi, A;Wang, Q;Gao, N;Xie, X;Su, X;Xiao, J;
    Year
    2020
    Journal
    bioRxiv
  • Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response
    Author
    Routhu, N;Gangadhara, S;Cheedarla, N;Shiferaw, A;Rahman, S;Sahoo, A;Shi, P;Menachery, V;Floyd, K;Fischinger, S;Atyeo, C;Alter, G;Suthar, M;Amara, R;
    Year
    2020
    Journal
    bioRxiv
  • Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins
    Author
    Zhang, Y;Zhao, W;Mao, Y;Chen, Y;Wang, S;Zhong, Y;Su, T;Gong, M;Du, D;Lu, X;Cheng, J;Yang, H;
    Year
    2020
    Journal
    bioRxiv
    Application
    N-glycosylation Characterization by MS
添加购物车成功! 添加购物车失败!请再次尝试 正在更新购物车,请稍后 U.S.A.